Regeneron Partners With AbbVie, Alnylam, AstraZeneca, Biogen, Pfizer to Sequence UK Biobank Samples

Jan 08, 2018

|

NEW YORK (GenomeWeb) – Regeneron Pharmaceuticals said today that it has formed a pre-competitive consortium with AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, and Pfizer to sequence the exomes of all 500,000 participants in the UK Biobank.

"All of us involved have a shared belief in the power of genetics to facilitate and guide drug discovery and development," said Aris Baras, vice president and head of the Regeneron Genetics Center (RGC), a wholly-owned subsidiary of Regeneron.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

Featured White Papers

Modular DNA Assembly of PIK3CA Using Acoustic Liquid Transfer in Nanoliter Volumes

Effective Miniaturization of Illumina Nextera XT Library Prep for Multiplexed Whole Genome Sequencing and Microbiome Applications

High-Throughput Microliter-Sized Cell-Free Transcription-Translation Reactions for Synthetic Biology Applications Using the Echo 550 Liquid Handler

Miniaturized 16S rRNA Amplicon Sequencing with the Labcyte Echo 525 Liquid Handler for Metagenomic and Microbiome Studies

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

04

Featured Webinar

Software Tools for NGS-Based Diagnosis of CFTR-Related Diseases in Routine Practice

This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Main menu